• 1. Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, P. R. China;
  • 2. Structural Heart Disease Center, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences andPeking Union Medical College, Beijing, 100037, P. R. China;
  • 3. Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China;
  • 4. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China;
  • 5. Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, P. R. China;
  • 6. Department of Cardiac Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, P. R. China;
SHANG Xiaoke, Email: 14236338@qq.com
Export PDF Favorites Scan Get Citation

In recent years, with the continuous development and increasing maturity of interventional techniques, interventional treatment for congenital heart disease (CHD) has been progressively disseminated to county- and city-level hospitals in China. Concurrently, the standardized management of adult CHD (particularly patent foramen ovale) and the lifelong management of complex CHD are gaining increasing clinical attention, while the emergence of new techniques and products continuously advances the discipline. This article aims to review the new progress made in the field of interventional treatment for congenital heart disease in China during 2024. It specifically reviews and analyzes the following key aspects: (1) annual statistics on interventional closure procedures for CHD; (2) recent insights into patent foramen ovale closure; (3) advances in transcatheter pulmonary valve replacement; (4) interventional treatment and lifelong management strategies for complex CHD; (5) new interventional techniques for acquired heart disease; and (6) the application of artificial intelligence in CHD management. Through the synthesis and discussion of these topics, this article seeks to provide a detailed analysis of the current landscape of interventional treatment for CHD in China and project its future development trends.

Citation: ZHANG Changdong, ZHONG Yucheng, LI Geng, TIAN Jun, ZHANG Gejun, DONG Nianguo, FENG Yuan, ZHOU Daxin, WU Yongjian, CHEN Lianglong, SHANG Xiaoke. 2024 annual report of interventional treatment for congenital heart disease. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2025, 32(7): 909-918. doi: 10.7507/1007-4848.202504082 Copy

Copyright © the editorial department of Chinese Journal of Clinical Thoracic and Cardiovascular Surgery of West China Medical Publisher. All rights reserved

  • Previous Article

    Chinese expert consensus on surgical treatment of congenital heart disease: Unilateral absence of a pulmonary artery
  • Next Article

    Interpretation of "Use of artificial intelligence in improving outcomes in heart disease: A scientific statement from the American Heart Association"